Systematic Follow up of Second Line Treatments for Parkinson's Disease (Deep Brain Stimulation, Apomorphin Pump, Duodopa Pump) (TeSLa-PD)

University Hospital, Strasbourg, France

Status: Not yet enrolling

Conditions: Parkinson's Disease

Study type: Observational

Funder types: Other

Identifiers

NCT05072015

8355

Details and patient eligibility

About

Primary purpose: Fluctuations and dyskinesia evolution in Parkinson's disease patients, one year after initiation of deep brain stimulation, apomorphin pump or duodopa pump

Secundary purposes:

• Motor complications evolution at 6 months, 2 and 3 years
• MDS UPDRS III score at 6 months, 1, 2 and 3 years
• non motor complications evolution at 6 months, 1, 2 and 3 years
• cognition and psychiatric complications evolution at 6 months, 1, 2 and 3 years
• cutaneous and digestive complications at 6 months, 1, 2 and 3 years
• neuropathy occurrence at 6 months, 1, 2 and 3 years
• medical treatment and Levodopa equivalent dose modifications at 6 months, 1, 2 and 3 years

Enrollment: 150 estimated patients

Sex: All

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Parkinson disease (UKPDSSB criteria)
• Patient with fluctuations and/or dyskinesia , who need treatment with deep brain stimulation, apomorphin pump or duodopa pump
• MOCA >20
• patient >21 years of age
• patient who has signed protocol acceptation

Exclusion criteria

• patient who did not give his acceptation for the protocol
• patient with another parkinsonian syndrome than Parkinson' s disease
• MOCA<20
• Patient who does not need second line treatment